Clinical Trial

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Name: Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis — clinical trial record (NCT07451665)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: VIVA-TAK

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.

Trial Details

NCT Number	NCT07451665
Lead Sponsor	Chinese SLE Treatment And Research Group
Conditions	Takayasu Arteritis (TAK)
Enrollment	180 participants
Start Date	2026-04-01
Primary Completion	2029-03-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-05